Literature DB >> 18824522

A null allele impairs function of CYP2C76 gene in cynomolgus monkeys: a possible genetic tool for generation of a better animal model in drug metabolism.

Yasuhiro Uno1, Hiroko Sakuraba, Shotaro Uehara, Takayuki Kumano, Kiyomi Matsuno, Chika Nakamura, Go Kito, Tetsuya Kamataki, Ryoichi Nagata.   

Abstract

The monkey CYP2C76 gene does not correspond to any of the human CYP2C genes, and its enzyme is at least partly responsible for the species difference occasionally seen in drug metabolism between monkeys and humans. To establish a line and/or lines of monkeys that are expected to show metabolic patterns highly similar to humans, we set out to find monkeys that lacked CYP2C76 activity. By genetic screening of 73 monkeys and a database search of expressed sequence tags, we found a total of 10 nonsynonymous genetic variants in the coding region of CYP2C76, including a null genotype (c.449TG>A). Some of the variants were differently distributed between two animal groups originating from different geographical regions (Indochina and Indonesia). After screening 170 additional genomic samples, we identified a total of eight animals (six males and two females) that were heterozygous for c.449TG>A, which could be used for establishing a homozygous line. If the homozygotes show drug-metabolizing properties more similar to humans than wild-type monkeys, the homozygotes may serve as a better animal model for drug metabolism. The data presented in this article provide the essential genetic information to perform a successful study by using cynomolgus monkeys and present a possible tool to generate a better animal model for drug metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824522     DOI: 10.1124/dmd.108.023622

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Single nucleotide polymorphisms in the FcγR3A and TAP1 genes impact ADCC in cynomolgus monkey PBMCs.

Authors:  Jonathan C Sanford; Hong Wu; Yasmina Abdiche; Julie A Harney; Javier Chaparro-Riggers; Karissa Adkins
Journal:  Immunogenetics       Date:  2017-02-03       Impact factor: 2.846

2.  CYP2D44 polymorphisms in cynomolgus and rhesus macaques.

Authors:  Yasuhiro Uno; Shotaro Uehara; Sakae Kohara; Naoki Osada; Norie Murayama; Hiroshi Yamazaki
Journal:  Mol Biol Rep       Date:  2015-02-15       Impact factor: 2.316

Review 3.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

4.  Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine.

Authors:  Shotaro Uehara; Norie Murayama; Yasuharu Nakanishi; Chika Nakamura; Takanori Hashizume; Darryl C Zeldin; Hiroshi Yamazaki; Yasuhiro Uno
Journal:  Xenobiotica       Date:  2014-08-20       Impact factor: 1.908

5.  Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys.

Authors:  Shotaro Uehara; Norie Murayama; Yasuharu Nakanishi; Darryl C Zeldin; Hiroshi Yamazaki; Yasuhiro Uno
Journal:  J Pharmacol Exp Ther       Date:  2011-08-17       Impact factor: 4.030

6.  Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey.

Authors:  Yasuhiro Uno; Shotaro Uehara; Sakae Kohara; Kazuhide Iwasaki; Ryoichi Nagata; Koichiro Fukuzaki; Masahiro Utoh; Norie Murayama; Hiroshi Yamazaki
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

7.  Isolation and characterization of arylacetamide deacetylase in cynomolgus macaques.

Authors:  Yasuhiro Uno; Masakiyo Hosokawa; Teruko Imai
Journal:  J Vet Med Sci       Date:  2015-02-07       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.